Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-247

  1. 134 Posts.
    lightbulb Created with Sketch. 40
    Among responding patients in the T-VEC arm, median time to response was 4.1 months, and more than half experienced ≥ 25% increase in the size of lesions or appearance of new lesions before achieving a response. This pattern of pseudoprogression is consistent with that seen with other immunotherapies19–23
    The full quote is above.
    It reads as half the responders are having psuedoprogression is how I see that.
    And then haven’t looked at your other article of 15%, but sounds like much higher than other immunotherapies.

    And this is what CF33 is meant to outperform, and they’ve compared to preclinically, so don’t think it would be a stretch for CF33 rates to be higher still.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
37.5¢
Change
0.005(1.35%)
Mkt cap ! $82.39M
Open High Low Value Volume
37.0¢ 37.5¢ 36.0¢ $342.2K 938.4K

Buyers (Bids)

No. Vol. Price($)
1 488 37.0¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 12566 2
View Market Depth
Last trade - 16.10pm 18/07/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.